Background: Genetic variation influencing individual susceptibility to chemical carcinogens is one of the main factors leading to cancer development. The glutathione S- transferases (GST) belong to a phase II enzymes family involved in detoxification of xenobiotics. We aimed to study GSTP1
(I1e105Val) variants in AML adult patients and identify its association with the development and progression of the disease. Patients and Methods: We investigated the influence of inherited GSTP1 (Ile 105 Val) gene polymorphism on the susceptibility to AML in 50 AML adult patients, together with 50 healthy controls with matched age and sex using [PCR-RFLP] assay. Results: We found that there was no significant differences between different GSTP1 genotypes according to clinical outcome in AML patients [Complete Remission, 29 patients (58%, P =0.274), Refractory Disease, 7 patients (14%, P=1.0), Induction Death, 14 patients (14%, P=0.418), Relapse, 6 patients (12%, p=0.217), Total Mortality, 31 patients (62%,P=0.152). GSTP1 Val/Val genotype and Val allele showed significantly higher frequency in AML cases with higher risk to develop AML(OR=6, 95% CI=1.242-28.987, pc=0.042; OR=2.082, 95% CI= 1.116-3.884, pc=0.040). Also, there was no significant differences found between GSTP1 genotypes regarding OS (P=0.434) and DFS (P=0.254) in AML groups. Conclusion: GSTP1 Ile105Val polymorphism has no significant effect on the development, the response to treatment or the survival of the AML patients, but (Val/Val) polymorphism had increased risk for developing it.
|
